

Wolfgang A Schulz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3447115/wolfgang-a-schulz-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

6,821
citations

44
h-index

69
g-index

222
ext. papers

7,594
ext. citations

5.9
avg, IF

5.7
L-index

#	Paper	IF	Citations
201	Retraction Note: Aging-associated distinctive DNA methylation changes of LINE-1 retrotransposons in pure cell-free DNA from human blood.. <i>Scientific Reports</i> , 2022 , 12, 3286	4.9	0
200	Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
199	The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells. <i>Anticancer Research</i> , 2021 , 41, 5987-5996	2.3	2.3
198	Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells. <i>Anticancer Research</i> , 2021 , 41, 2901-2912	2.3	0
197	Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. <i>Genes</i> , 2021 , 12,	4.2	4
196	Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. <i>Cancers</i> , 2021 , 13,	6.6	1
195	Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. <i>Cancers</i> , 2020 , 12,	6.6	14
194	Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. <i>Scientific Reports</i> , 2020 , 10, 3808	4.9	2
193	Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. <i>Cancers</i> , 2020 , 12,	6.6	2
192	Aging-associated distinctive DNA methylation changes of LINE-1 retrotransposons in pure cell-free DNA from human blood. <i>Scientific Reports</i> , 2020 , 10, 22127	4.9	7
191	In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
190	Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
189	Oxidative stress and LINE-1 reactivation in bladder cancer are epigenetically linked through active chromatin formation. <i>Free Radical Biology and Medicine</i> , 2019 , 134, 419-428	7.8	14
188	HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
187	Contingencies of UTX/KDM6A Action in Urothelial Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	16
186	Detailed methylation map of LINE-1 5Qpromoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity. <i>Molecular Genetics & Genomic Medicine</i> , 2019 , 7, e601	2.3	15
185	Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma. <i>BMC Cancer</i> , 2019 , 19, 806	4.8	18

184	The histone demethylase UTX/KDM6A in cancer: Progress and puzzles. <i>International Journal of Cancer</i> , 2019 , 145, 614-620	7.5	33
183	Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. <i>Scientific Reports</i> , 2019 , 9, 14476	4.9	3
182	ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53. <i>MBio</i> , 2019 , 10,	7.8	8
181	Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. <i>Scientific Reports</i> , 2018 , 8, 3477	4.9	7
180	Effects of novel HDAC inhibitors on urothelial carcinoma cells. <i>Clinical Epigenetics</i> , 2018 , 10, 100	7.7	38
179	Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer. <i>Frontiers in Physiology</i> , 2018 , 9, 456	4.6	19
178	USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1. <i>Journal of Virology</i> , 2018 , 92,	6.6	16
177	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
176	Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. <i>Clinical Epigenetics</i> , 2018 , 10, 1	7.7	47
175	Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. <i>PLoS ONE</i> , 2018 , 13, e0190854	3.7	27
174	LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 143-151	3.3	9
173	APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression. <i>Frontiers in Microbiology</i> , 2018 , 9, 2088	5.7	10
172	Analysis of DNA methylation in single circulating tumor cells. <i>Oncogene</i> , 2017 , 36, 3223-3231	9.2	49
171	Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 544.e1-544.e10	2.8	13
170	Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 544.e11-544.e23	2.8	13
169	Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. <i>PLoS ONE</i> , 2017 , 12, e0176287	3.7	35
168	Does HERV-K represent a potential therapeutic target for prostate cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 921-924	6.4	5
167	6. Symposium des Deutschen Forschungsverbunds Blasenkarzinom. <i>Der Urologe</i> , 2017 , 56, 806-807		

166	Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 1	12.8	55
165	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	8
164	Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
163	HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment. <i>Current Medicinal Chemistry</i> , 2017 , 24, 4151-4165	4.3	13
162	Altered expression of LINC-ROR in cancer cell lines and tissues. <i>Tumor Biology</i> , 2016 , 37, 1763-9	2.9	26
161	Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. <i>Targeted Oncology</i> , 2016 , 11, 783-798	5	33
160	Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 299-312	6.1	35
159	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. <i>Molecular Oncology</i> , 2016 , 10, 825-37	7.9	18
158	The Role of Embryonic Stem Cell-expressed RAS (ERAS) in the Maintenance of Quiescent Hepatic Stellate Cells. <i>Journal of Biological Chemistry</i> , 2016 , 291, 8399-413	5.4	18
157	Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. <i>Oncotarget</i> , 2016 , 7, 41320-41335	3.3	8
156	The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors. <i>Bladder Cancer</i> , 2016 , 2, 449-463	1	24
155	DNA methylation in urothelial carcinoma. <i>Epigenomics</i> , 2016 , 8, 1415-1428	4.4	16
154	Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs. <i>Clinical Epigenetics</i> , 2015 , 7, 17	7.7	30
153	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. <i>BMC Genomics</i> , 2015 , 16, 403	4.5	59
152	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 144	12.8	20
151	Human endogenous retrovirus HERV-K(HML-2) activity in prostate cancer is dominated by a few loci. <i>Prostate</i> , 2015 , 75, 1958-71	4.2	27
150	Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. <i>Non-coding RNA</i> , 2015 , 1, 266-284	7.1	14
149	Characterization of DNA Methylation in Circulating Tumor Cells. <i>Genes</i> , 2015 , 6, 1053-75	4.2	34

148	The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. <i>Molecular Cancer</i> , 2015 , 14, 108	42.1	57
147	Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. <i>Tumor Biology</i> , 2015 , 36, 3293-300	2.9	15
146	Epigenetics of urothelial carcinoma. <i>Methods in Molecular Biology</i> , 2015 , 1238, 183-215	1.4	11
145	Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1051-60	2.8	15
144	Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 59	12.8	24
143	MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 670-7	2.8	23
142	Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer. <i>Oncology Research and Treatment</i> , 2014 , 37, 492-8	2.8	9
141	Deregulation of an imprinted gene network in prostate cancer. <i>Epigenetics</i> , 2014 , 9, 704-17	5.7	44
140	Canonical Notch signalling is inactive in urothelial carcinoma. <i>BMC Cancer</i> , 2014 , 14, 628	4.8	21
139	Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. <i>Cancer Biology and Therapy</i> , 2014 , 15, 742-57	4.6	28
138	Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 20500-17	6.3	18
137	Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. <i>Clinical Epigenetics</i> , 2014 , 6, 29	7.7	26
136	Urothelial Carcinoma 2014 , 1-8		
135	Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma. <i>Cancer Genomics and Proteomics</i> , 2014 , 11, 141-53	3.3	4
134	Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 622-7	2.8	26
133	Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1770-9	2.8	55
132	HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2013 , 3, 255	5.3	36
131	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3250-8	2.2	102

130	Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines. <i>Cellular Oncology (Dordrecht)</i> , 2012 , 35, 243-57	7.2	11
129	Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation. <i>Asian Journal of Andrology</i> , 2012 , 14, 436-50	2.8	22
128	DNA methylation changes in prostate cancer. <i>Methods in Molecular Biology</i> , 2012 , 863, 47-66	1.4	45
127	Molekulare Onkologie. <i>Onkologe</i> , 2012 , 18, 1023-1028	0.1	0
126	The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer. <i>International Journal of Cancer</i> , 2012 , 131, E897-904	7.5	13
125	ID4 is frequently downregulated and partially hypermethylated in prostate cancer. <i>World Journal of Urology</i> , 2012 , 30, 319-25	4	20
124	Hedgehog signaling regulates bladder cancer growth and tumorigenicity. <i>Cancer Research</i> , 2012 , 72, 4449-58	10.1	36
123	Stem cells in the biology of normal urothelium and urothelial carcinoma. <i>Neoplasma</i> , 2012 , 59, 728-36	3.3	37
122	The Impact of Epigenetic Alterations on Diagnosis, Prediction, and Therapy of Prostate Cancer 2012 , 123-157		1
121	S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. <i>PLoS ONE</i> , 2011 , 6, e27509	3.7	69
120	The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 1210-24	5.6	41
119	Insights into cancer mechanisms from genomic research on urological cancers. <i>Genome Medicine</i> , 2011 , 3, 20	14.4	1
118	Selective changes of retroelement expression in human prostate cancer. <i>Carcinogenesis</i> , 2011 , 32, 1484-92	4.6	64
117	The role of c-FLIP splice variants in urothelial tumours. <i>Cell Death and Disease</i> , 2011 , 2, e245	9.8	12
116	Recent insights into regulation of transcription by RNA polymerase III and the cellular functions of its transcripts. <i>Biological Chemistry</i> , 2011 , 392, 395-404	4.5	12
115	DNA Methylation and the HOXC6 Paradox in Prostate Cancer. <i>Cancers</i> , 2011 , 3, 3714-25	6.6	17
114	Eagles report: Developing cancer biomarkers from genome-wide DNA methylation analyses. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 1-7	2.5	5
113	Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. <i>Tumor Biology</i> , 2010 , 31, 297-307	2.9	61

112	Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. <i>Cell Biology and Toxicology</i> , 2010 , 26, 553-67	7.4	68
111	Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. <i>BMC Cancer</i> , 2010 , 10, 505	4.8	36
110	Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. <i>Cancer Genomics and Proteomics</i> , 2010 , 7, 51-60	3.3	24
109	Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. <i>Cancer Research</i> , 2009 , 69, 1527-35	10.1	62
108	Epigenetic mechanisms in the biology of prostate cancer. <i>Seminars in Cancer Biology</i> , 2009 , 19, 172-80	12.7	56
107	Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. <i>Cell Proliferation</i> , 2009 , 42, 762-9	7.9	38
106	DKC1 overexpression associated with prostate cancer progression. <i>British Journal of Cancer</i> , 2009 , 101, 1410-6	8.7	71
105	Absence of PIWIL2 (HILI) expression in human bladder cancer cell lines and tissues. <i>Cancer Epidemiology</i> , 2009 , 33, 271-5	2.8	13
104	A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein. <i>Blood</i> , 2009 , 114, 572-9	2.2	31
103	Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008 , 638, 56-65	3.3	17
102	Genetic variation of Aflatoxin B1 aldehyde reductase genes (AFAR) in human tumour cells. <i>Cancer Letters</i> , 2008 , 272, 160-6	9.9	11
101	Do DNA-methylation changes also occur in blood?. <i>Lancet Oncology, The</i> , 2008 , 9, 312-3	21.7	4
100	Chromosomal instability in bladder cancer. <i>Archives of Toxicology</i> , 2008 , 82, 173-82	5.8	30
99	Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. <i>International Journal of Cancer</i> , 2008 , 123, 2798-807	7.5	35
98	Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome. <i>Molecular Reproduction and Development</i> , 2008 , 75, 1484-94	2.6	26
97	Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. <i>Cancer Genomics and Proteomics</i> , 2008 , 5, 123-36	3.3	27
96	Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. <i>Molecular Cancer</i> , 2007 , 6, 14	42.1	40
95	Disruption of the FA/BRCA pathway in bladder cancer. <i>Cytogenetic and Genome Research</i> , 2007 , 118, 166-76	1.9	35

94	Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. <i>Cancer</i> , 2007 , 109, 2016-24	6.4	43
93	Downregulation of several fibulin genes in prostate cancer. <i>Prostate</i> , 2007 , 67, 1770-80	4.2	87
92	In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. <i>Experimental and Molecular Pathology</i> , 2007 , 82, 292-7	4.4	28
91	A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. <i>World Journal of Urology</i> , 2007 , 25, 297-302	4	19
90	Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1403-12	4.6	61
89	Transcription factor networks in embryonic stem cells and testicular cancer and the definition of epigenetics. <i>Epigenetics</i> , 2007 , 2, 37-42	5.7	20
88	Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. <i>American Journal of Epidemiology</i> , 2007 , 165, 1221-30	3.8	68
87	Epigenetics of prostate cancer: beyond DNA methylation. <i>Journal of Cellular and Molecular Medicine</i> , 2006 , 10, 100-25	5.6	84
86	Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. <i>European Urology</i> , 2006 , 49, 169-75; discussion 175	10.2	12
85	Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. <i>Biochemical Pharmacology</i> , 2006 , 72, 1577-88	6	69
84	Imbalances of chromosome arm 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 995-1006	5	26
83	Understanding urothelial carcinoma through cancer pathways. <i>International Journal of Cancer</i> , 2006 , 119, 1513-8	7.5	90
82	DNA methylation alterations in urothelial carcinoma. <i>Cancer Biology and Therapy</i> , 2006 , 5, 993-1001	4.6	44
81	L1 retrotransposons in human cancers. <i>Journal of Biomedicine and Biotechnology</i> , 2006 , 2006, 83672		70
80	Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. <i>Molecular Cancer Research</i> , 2006 , 4, 169-76	6.6	47
79	Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation. <i>European Journal of Cancer</i> , 2006 , 42, 264-74	7.5	15
78	Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. <i>Endocrine-Related Cancer</i> , 2006 , 13, 839-49	5.7	64
77	Causes and consequences of DNA hypomethylation in human cancer. <i>Biochemistry and Cell Biology</i> , 2005 , 83, 296-321	3.6	203

76	Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. <i>Molecular Cancer</i> , 2005 , 4, 16	42.1	46
75	Hypomethylation of the XIST gene promoter in prostate cancer. <i>Oncology Research</i> , 2005 , 15, 257-64	4.8	28
74	Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. <i>Journal of Cellular Physiology</i> , 2005 , 203, 372-7	7	22
73	Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 58-67	5	41
72	Multiple mechanisms downregulate CDKN1C in human bladder cancer. <i>International Journal of Cancer</i> , 2005 , 114, 406-13	7.5	51
71	Methylenetetrahydrofolate reductase C677T polymorphism and risk of adenocarcinoma of the upper gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , 2005 , 40, 109-11	2.4	17
70	Estimating cancer survival and clinical outcome based on genetic tumor progression scores. <i>Bioinformatics</i> , 2005 , 21, 2438-46	7.2	41
69	DNA Methylation in Urological Cancers 2005 , 42-58		
68	Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. <i>Clinical Chemistry</i> , 2005 , 51, 649-52	5.5	23
67	Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. <i>Oncogene</i> , 2004 , 23, 3541-9	9.2	75
66	Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. <i>British Journal of Cancer</i> , 2004 , 91, 985-94	8.7	146
65	Methylenetetrahydrofolate reductase C677T polymorphism and predisposition towards esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 574-80	4.9	25
64	Denaturing high-performance liquid chromatography (DHPLC) as a reliable high-throughput prescreening method for aberrant promoter methylation in cancer. <i>Human Mutation</i> , 2004 , 23, 612-20	4.7	14
63	Suppression of clonogenicity by mammalian Dnmt1 mediated by the PCNA-binding domain. <i>Biochemistry and Cell Biology</i> , 2004 , 82, 589-96	3.6	3
62	Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. <i>Urology</i> , 2004 , 63, 392-7	1.6	21
61	Molecular biology of prostate cancer. <i>Molecular Human Reproduction</i> , 2003 , 9, 437-48	4.4	36
60	Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. <i>Molecular Genetics and Genomics</i> , 2003 , 270, 394-402	3.1	36
59	Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. <i>European Urology</i> , 2003 , 43, 309-19	10.2	76

58	Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. <i>Experimental and Molecular Pathology</i> , 2003 , 74, 262-6	4.4	11
57	Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. <i>Genes Chromosomes and Cancer</i> , 2003 , 37, 141-8	5	36
56	Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. <i>International Journal of Cancer</i> , 2003 , 104, 568-78	7.5	42
55	Association between NAD(P)H: quinone oxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. <i>International Journal of Cancer</i> , 2003 , 107, 381-6	7.5	53
54	E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. <i>British Journal of Cancer</i> , 2003 , 88, 1932-8	8.7	36
53	Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. <i>Experimental Cell Research</i> , 2003 , 282, 48-57	4.2	64
52	Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. <i>Carcinogenesis</i> , 2003 , 24, 905-9	4.6	66
51	DNA methylation in placentas of interspecies mouse hybrids. <i>Genetics</i> , 2003 , 165, 223-8	4	12
50	Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. <i>Genes Chromosomes and Cancer</i> , 2002 , 35, 58-65	5	142
49	Tumour class prediction and discovery by microarray-based DNA methylation analysis. <i>Nucleic Acids Research</i> , 2002 , 30, e21	20.1	218
48	p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. <i>Urologia Internationalis</i> , 2002 , 69, 174-80	1.9	15
47	Activity of E2F-dependent promoters in bladder carcinoma cells and their use for tumour-specific targeting of p53-induced apoptosis 2002 , 21, 1033		
46	Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. <i>Prostate</i> , 2002 , 50, 135-44	4.2	19
45	Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. <i>Molecular Carcinogenesis</i> , 2001 , 32, 36-43	5	34
44	Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. <i>British Journal of Cancer</i> , 2001 , 85, 1887-93	8.7	42
43	Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. <i>Mutation Research - Mutation Research Genomics</i> , 2001 , 458, 49-54		14
42	Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. <i>Prostate</i> , 2000 , 45, 225-31	4.2	43
41	Novel mutations of the von Hippel-Lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type. <i>International Journal of Cancer</i> , 2000 , 87, 650-653	7.5	21

40	DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. <i>Laboratory Investigation</i> , 2000 , 80, 1513-22	5.9	47
39	Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association. <i>Archives of Toxicology</i> , 2000 , 74, 222-5	5.8	38
38	Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. <i>Archives of Toxicology</i> , 2000 , 74, 521-6	5.8	90
37	Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. <i>Urology</i> , 2000 , 56, 689-95	1.6	19
36	DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. <i>British Journal of Cancer</i> , 1999 , 80, 1312-21	8.7	211
35	Over-expression and amplification of the c-myc gene in human urothelial carcinoma. <i>International Journal of Cancer</i> , 1999 , 84, 169-73	7.5	30
34	High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. <i>Prostate</i> , 1999 , 39, 166-74	4.2	139
33	Identification of the physiological promoter for spinocerebellar ataxia 2 gene reveals a CpG island for promoter activity situated into the exon 1 of this gene and provides data about the origin of the nonmethylated state of these types of islands. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 254, 315-8	3.4	13
32	High frequency of alterations in DNA methylation in adenocarcinoma of the prostate 1999 , 39, 166		1
31	High frequency of alterations in DNA methylation in adenocarcinoma of the prostate 1999 , 39, 166		2
30	Expression of G1-->S transition regulatory molecules in human urothelial cancer. <i>Japanese Journal of Cancer Research</i> , 1998 , 89, 719-26		21
29	Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid. <i>Biological Chemistry</i> , 1998 , 379, 1083-91	4.5	16
28	Predisposition towards urolithiasis associated with the NQO1 null-allele. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 453-4		17
27	Predictive value of molecular alterations for the prognosis of urothelial carcinoma. <i>Cancer Detection and Prevention</i> , 1998 , 22, 422-9		8
26	Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 235-9		130
25	c-myc in bladder cancer. Clinical findings and analysis of mechanism. <i>Urological Research</i> , 1997 , 25 Suppl 1, S45-9		29
24	Induction of mouse embryonal carcinoma cell differentiation and activation of the retinoic acid receptor beta 2 promoter by 1,25-dihydroxyvitamin D3. <i>Biological Chemistry Hoppe-Seyler</i> , 1996 , 377, 703-10		
23	Adjacent guanines as preferred sites for strand breaks in plasmid DNA irradiated with 193 nm and 248 nm UV laser light. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 1996 , 32, 97-102	6.7	30

22	Positive and negative regulatory regions in promoters of human glutathione transferase alpha genes. <i>Biological Chemistry Hoppe-Seyler</i> , 1996 , 377, 39-46		8
21	Free radicals in toxicology: redox cycling and NAD(P)H:quinone oxidoreductase. <i>Archives of Toxicology Supplement</i> , 1996 , 18, 217-22		5
20	Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. <i>Urological Research</i> , 1995 , 23, 293-300		43
19	Efficacy of all-trans-beta-carotene, canthaxanthin, and all-trans-, 9-cis-, and 4-oxoretinoic acids in inducing differentiation of an F9 embryonal carcinoma RAR beta-lacZ reporter cell line. <i>Archives of Biochemistry and Biophysics</i> , 1995 , 316, 665-72	4.1	52
18	Induction of gap junctional communication by 4-oxoretinoic acid generated from its precursor canthaxanthin. <i>Archives of Biochemistry and Biophysics</i> , 1995 , 317, 423-8	4.1	75
17	Turnover of glutathione S-transferase alpha mRNAs is accelerated by 12-O-tetradecanoyl phorbol-13-acetate in human hepatoma and colon carcinoma cell lines. <i>FEBS Journal</i> , 1995 , 229, 21-6		4
16	Regulation of DNA methyltransferase during differentiation of F9 mouse embryonal carcinoma cells. <i>Journal of Cellular Physiology</i> , 1995 , 165, 284-90	7	21
15	Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. <i>Biological Chemistry Hoppe-Seyler</i> , 1994 , 375, 439-45		36
14	Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines. <i>Carcinogenesis</i> , 1994 , 15, 219-25	4.6	36
13	Exemption of satellite DNA from demethylation in immortalized differentiated derivatives of F9 mouse embryonal carcinoma cells. <i>Experimental Cell Research</i> , 1994 , 210, 192-200	4.2	9
12	Localization of strand breaks in plasmid DNA treated with reactive oxygen species. <i>Methods in Enzymology</i> , 1994 , 234, 45-51	1.7	9
11	Highly efficient transactivation by the yeast <i>Kluyveromyces lactis</i> transcription factor LAC9 and its inhibition by the negative regulator GAL80 in mammalian cells. <i>Biological Chemistry Hoppe-Seyler</i> , 1993 , 374, 313-8		9
10	Gene order and genetic distance of 13 loci spanning murine chromosome 15. <i>Genomics</i> , 1992 , 14, 417-22	4.3	5
9	De novo methylation of transfected CAT gene plasmid constructs in F9 mouse embryonal carcinoma cells. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1992 , 1131, 16-22		14
8	Distribution and DNA methylation of a repetitive promoter sequence cloned from mouse embryonal carcinoma cells. <i>Biological Chemistry Hoppe-Seyler</i> , 1991 , 372, 1073-9		
7	Formation of 8-hydroxy(deoxy)guanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. <i>Biochemistry</i> , 1991 , 30, 6283-9	3.2	276
6	A comparative analysis of N-myc and c-myc expression and cellular proliferation in mouse organogenesis. <i>Mechanisms of Development</i> , 1991 , 33, 119-25	1.7	94
5	Coexpression of the c-myc protooncogene with alpha-fetoprotein and albumin in fetal mouse liver. <i>Differentiation</i> , 1990 , 45, 96-102	3.5	29

4	Heterozygous expression of X-linked chondrodysplasia punctata. Complex chromosome aberration including deletion of MIC2 and STS. <i>Human Genetics</i> , 1990 , 86, 215-8	6.3	4
3	A comparative study of the heterochromatin of <i>Apodemus sylvaticus</i> and <i>Apodemus flavicollis</i> . <i>Chromosoma</i> , 1989 , 98, 450-455	2.8	24
2	Constitutive c-myc expression enhances proliferation of differentiating F9 teratocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1989 , 1013, 125-32	4.9	14
1	Albumin and alpha-fetoprotein gene expression and DNA methylation in rat hepatoma cell lines. <i>Experimental Cell Research</i> , 1988 , 174, 433-47	4.2	33